Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist PRESENT PROFESSIONAL POSITION OPHTALMOLOGIST DOCTOR, Private practice Retinal medical Specialist, DMLA in particular Installation year : 1988 TRAINING (1976-1986) : General Medical Practice and SPECIALITY 1977 : Human Biology Grade 1987 Medical Doctor Degree THESIS : Macular sub-retinal neovascularisation and its treatment with Krypton laser. General review, computer clinical and angiographical study. Treatment results for the 85 studied cases. CES of OPHTHALMOLOGY, Ophthalmology Medical Specialist Degree PROFESSIONAL EXPERIENCE 1988 2010 Private practice Ophthalmology, Retinal Medical Specialty and AMD, private office Marked by a dot and underlined, underneath are the medical exams,which I have been the first to introduce in the Region Midi Pyrénées! Angiographies : - FA (Fluorescein Angiography), since 1988 - ICG (Infracyanin Green Angiography), since 1992 - SPECTRALIS and SPECTRALIS OCT Angiography, since 2007 Until now I have been the only physician in the Midi Pyrénées Region to have a common practice of Spectralis system FA and ICG, retinal and optic nerve Spectral domain OCT.! Laser : all types, including multi waves,since 1988! OCT 3 (Optic Confocal Tomography), since 1995! Photodynamic Therapy, since 2000! IVT (Intra-Vitreal Injection),1 er surgical unit in Private office in Midi-Pyrénées, since 2005 (only 10 surgical units like this in France) HIV ophthalmologic Pathology Contactology 1
RESEARCH BACKGROUND Fundamental Research 1989 1991 Professeur Soleihavoup Laboratory ( Histo-Cytology department, Purpan CHU Toulouse) Antikératin antibody profiling of retinal pigment epithelium. publication about this work : n 20 reference below Based on the results obtained during this period, I submitted many working hypothesis about ARMD etiopathogenesis, with the specific retinal pigment epithelium role and in particular mitochondrial pigment epithelium dysfunction. Those hypothesis were based on regular scientific literature revue and clinical studies published in an international way by well known teams. At this time, I have established links with other researchers in the course of many meetings. Interest for a coordinated research These contacts referred to above have for a few of them become permanent and I am looking for teams able to cooperate together in order to demonstrate and confirm those hypothesis. I would like to federate several research teams to make them more dynamic and productive. The basic idea is to get them together, taking advantage of their specific competences, cross fertilize between the groups with a common goal which is to better understand AMD pathogenesis and more over retinal pathologies. In this respect, it is a common feature of the pharma industry that research is terribly expensive and that a lot of duplication is going on, at a tremendous cost. I believe that, as it is presently done for ALZHEIMER s disease, where a number of pharma companies are beginning to work on a common project, the same kind of research could be developed for AMD, because it is simply not true that fundamental research is competitive in the economic sense of the word. In particular, findings of toxicity in the research programs should be shared between the companies, which would improve the speed at which innovation can be brought into the sector. This could also be a very interesting topic for a joint funding between the industry and the EU Research and Development Framework Programme. Clinical Research Absolutely aware of the scientific progress importance in medical practice, and always seeking for innovation, I ve been precursor : - In the retinal pathologies investigative techniques use (cf ref n 8,26,28,30,33) - In the therapeutic principles use : PED treatment (cf ref n 15), «Baxter» principle use development for CMV retinitis treatment, of Thalidomide, for SIDA patients (cf ref n 22,27) - In new treatments development : no steroid anti-inflammatory treatments in general and/or subconjunctival administration to treat exudative reactions and complications of ADM, Diabetic retinopathy, retinal vein occlusion (cf ref n 1, 2,3) - In new therapeutic protocol suggestions : retrofoveolar neovascular AMD complication treated with series of 3 IVT (cf ref n 9,10,11,12,4,5,6). Others international medical teams have confirmed this protocol, with similar results, much better and promising than those of other standard studies. (cf ARVO 2010 meeting abstracts and conferences) 2
- In having initiative in protocol and therapies : in contrast with usual practice, I recommend not to give Triamcinolone by IVT for the treatment of exudative reaction complicating AMD, Diabetic retinopathy, retinal vein occlusion ( now quite dropped method ) - In my medical practice of Ophthalmology : private practice, no in clinic and/or hospital, with surgical unit in the office SCIENTIFIC AND CLINICAL WORKS (published and /or presented in meetings) Internationals 1 - Diclofenac with photodynamic therapy for choroidal neovascularisation complicating AMD C Gonzales, ARVO 2005 and Mickaelson Meeting 2005 2 - Subconjonctival injection of triamcinolone and photodynamic therapy (PDT) for exsudative choroidal neovascularisation (CNV) complicating age macular degeneration (AMD) C Gonzalez, ARVO 2006 et Euretina 2007 3 - Subconjonctival injection of triamcinolone for the treatment of macular oedema complicating diabetic retinopathy C Gonzalez, ARVO 2007 4 - Intravitreal pegaptanib for retrofoveolar neovascular myopia maculopathy C Gonzalez, ARVO 2008 5 - Intravitreal pegaptanib for retrofoveolar neovascularisation complicating age macular degeneration (AMD), with predominant pigment epithelium(pe) atrophic areas C Gonzalez, Euretina 2008 6 - Analysis of intravitreal ranibizumab injections effects on exudative reaction complicating subfoveal choroidal neovascular age related macular degeneration (AMD) C Gonzalez, EVER 2008 7 - No functional vision improvement after intravitreal ranibizumab injections (IVT) for retrofoveolar choroidal neovascular age related macular degeneration (AMD),why? C Gonzalez, EVER 2008 8 - Interest of spectralis HRA + OCT for the follow-up of age macular degeneration (AMD),with and without neovascular complication C Gonzalez, Heidelberg meeting 2009 9 - Treatment of retrofoveolar neovascular AMD by series of 3 ranibizumab injections,1 year! follow-up 10 - Treatment of retrofoveolar neovascular AMD by 3 injections series of ranibizumab followed by maintenace treatment with 3 pegaptanib IVT after 1 year follow-up 11 - Treatment of retrofoveolar neovascular AMD by series of 3 ranibizumab injections,1 year! follow-up 12 - Treatment of retrofoveolar neovascular AMD by 3 injections series of ranibizumab followed by maintenace treatment with 3 pegaptanib IVT after 1 year follow-up 13 - Intravitreal pegaptanib for retrofoveolar neovascular age related macular degeneration, in pseudo vitelliform and/or drusenoid pigment epithelium detachment shape C Gonzalez, SOE 2009 14 - Intravitreal ranibizumab for retrofoveolar neovascular age related macular degeneration, in pseudo vitelliform and/or drusenoid pigment epithelium detachment shape C Gonzalez, SOE 2009 3
Europeans Publications in periodicals with reading committees 15 Retinal serous detachments. Interest of acetazolamide C Gonzalez. J.Fr. Ophtalmol., 1992 16 Study of contrast sensitivity in two groups of patients. Normal and amblyopic. C Gonzalez, C Labro-Leredde, Opthalmologies, 1999 17 Serous Drusen or micro-pigment epithelium detachment. Neovascular risk factor. C Gonzalez, Ophtalmologies, 1999 Communications 18 Subretinal new vessels treated by laser krypton photocoagulation. C Gonzalez, Société de Photocoagulation, 1987 19 Ocular fundus white spots C Gonzalez, Société Méditerranéenne du Midi, 1990 20 Antikeratin antibody profiling of retinal pigment epithelium cells C Gonzalez, Congrès international sur la macula, 1991 21 The high myopia new vessels. C Gonzalez, Congrès d Ophtalmologie, 1996 22 Interest of Thalidomide in the treatment of inflammation occuring with CMV chorioretinitis during VIH infection. C Gonzalez, M Obadia, S Averous, B Marchou, P Massip. Symposium «maladie à CMV au cours de l infection par le VIH», 1997 Nationals Publications in periodicals of specialty 23 The biometry : the iris, the retina : why, how, the ophthalmologist point of vue. C Gonzalez, Convergence, mai number, 2006 24 News, prospects, attitude about age macular degeneration ( AMD ) C Gonzalez, Journal Association Rétina France, february number, 2007 25 New prospects concerning medical retina C Gonzalez, Journal Association Rétina France, december number, 2008 Communication in meetings 26 Pigment epithelium degeneration :angiographic signs without complications C Gonzalez, SFO 1993 27 - CMV Retinopathy, «what about Thalidomide?» C Gonzalez, M Obadia, SOIF, 1998 28 - Late frame ICG hyperfluorescent pictures in AMD patients. C Gonzalez, SFO, 1999 29 New vessels and inflammation : clinical case report C Gonzalez, SOIE et SOIF, 2006 30 Interest and place of OCT in AMD and its neovascular complication follow-up C Gonzalez, SFO, 2007 31 - Pegaptanib intravitreal injections (IVT) for the treatment of AMD previously treated by Dynamic Phototherapy ( PDT ). C Gonzalez, SFO, 2008 32 Recurrences features after loading inductive anti-vegf ranibizumab (Lucentis) treatment C Gonzalez, SFO, 2009 4
33 AMD edemas, spectral domain OCT Interest C Gonzalez, SFO, 2010 Communications in specialist s meetings 34 - Dynamic Phototherapy, one year and a half after The treatment and its indications. The followup and the re-treatment indications C Gonzalez, Spécialists in Ophtalmology meeting, 2002 35 - AMD and therapeutic prospects C Gonzalez, Association Retina France meeting, 2002 36 - Occult New vessels PDT interest for the treatment of foveolar subretinal occult neovascularisation C Gonzalez, Novavision, 2003 et 2004 37 Last research marchs for new vessels treatment. PDT interest for the treatment of subretinal occult new vessels C Gonzalez, Spécialists in Ophtalmology meeting, 2004 38 - AMD and therapeutic prospects C Gonzalez, Spécialists in Ophtalmology meeting, 2004 39 OCT and AMD C Gonzalez, Spécialists in Ophtalmology meeting, 2005 40 - AMD: clinical cases report 41 - Angiography meeting 42 - AMD : Follow-up, Prospect, Screening, Prévention 43 - Angiogenesis: VEGF et anti-vegf (physiology & physiopathology) 44 - Anti- VEGF News C Gonzalez, FMC, 2007 45 - IVT unit in private practice and office C Gonzalez, DMLA en pratique, 2008 46 AMD and general practitioner C Gonzalez, FMC 2007 et 2010 ACTIVE MEMBER OF SCIENTIFIC GROUPS AND LEARNED SOCIETIES International AAO ARVO EURETINA EVER EVRS SOE SOIE SOIF National SFO 5